Abbott Moves From Meeting WIC Backlog To Distributing Formula Brands To Retailers
Executive Summary
Abbott’s US formula sales continued to fall during the October-December period on manufacturing disruptions even with production “up and running” at its Sturgis, MI, where it makes powder formula it markets under Similac, Alimentum and EleCare brands.
You may also be interested in...
Abbott Stops Using ‘#1 Infant Formula Brand’ Claim After Finding Supporting Data Out Of Date
Mead Johnson not only gains with Abbott stopping use of claim on Similac packaging, but also continues using similar claim on Enfamil packages, “#1 Pediatrician Recommended Brand.” In NAD report, Abbott says data backing up its claim apparently wasn’t current.
US Q1 Consumer Health Earnings Preview: Lifted By Welcome Changes, Or Slowed By Surprises?
An end to US COVID-19 PHE on 10 April doesn’t end inflationary pressure on prices for consumer packaged goods. OTC, supplements and personal care product firms could be reporting consumers during Q1 were going along with price increases, opting for less expensive options or buying less.
In Food Programs Restructuring, US FDA Has Designs On Clear Priorities, Chain Of Command
Following reviews prompted largely by formula supply crisis, FDA will move Center for Food Safety and Applied Nutrition and commissioner’s Office of Food Programs and Response to Human Foods Program headed by deputy commissioner. Office of Regulatory Affairs' structure also changing “to support the FDA organization as a whole,” says Commissioner Califf.